الفهرس 
Diabetic NeuropathyOnly 14 pages are availabe for public view
 |  | from | 120 |  |  |
| | | from | 120 | | |
Abstract
This was a cross-sectional study that was carried out in Menoufia
University Hospital, neurology department on 80 patients of both sexes, aged
30 to 60 years, divided into 4 groups, selected from December 2022 to
August 2023.
group 1: twenty (M=9, F=11) a control group .
group 2: twenty, (M=15, F=5) was diabetic not neuropathic patients.
Group3: twenty, (M=8, F=12) was diabetic neuropathic not
complaining of their neuropathy.
group 4: twenty, (M=14, F=6) was diabetic neuropathic complaining
of their neuropathy.
All of the study procedures were carried out and approved by the
ethical committee of the Faculty of Medicine, Menoufia University, in
December 2020.
Each of the studied groups was subjected to history taking, clinical
examination and laboratory investigations including serum HA1c, serum
level of interleukin 6 (IL6) and nerve conduction studies.
In our study, we compare serum level of IL6 in 4 groups, also we
studied the relation between nerve conduction studies of motor and sensory
nerves and the serum level of interleukin 6 (IL6) in all studied groups.
In our study, serum level of interleukin 6 (IL6) in type 2 diabetic
patients with painful neuropathy is higher than those with painless
neuropathy, and also higher than control group and diabetic not neuropathic
group.
We found statistically significant difference in mean CMAP
amplitude, DL and CV of both median and ulnar motor nerves among studied groups, with lowest mean CMAP amplitude, prolonged distal latencies,
slower conduction velocity in painful neuropathy group.
Also, in lower limbs there were highly statistically significant
differences in CMAP amplitude and CV of the peroneal and CMAP
amplitude and CV of tibial nerves, with lowest mean CMAP amplitude,
prolonged distal latencies, slower conduction velocity in painful neuropathy
group.
As regards, sensory nerve conduction studies, we had performed NCS
to all studied group, including median, ulnar, and sural sensory SNAP
amplitude and DL in diabetic patients with peripheral neuropathy and those
without neuropathy and also in non-diabetic control group and we found
highly statistically significant differences among the studied groups.
In our study, it has proven that IL6 has a role for detection of diabetic
painful neuropathy. We suggested that serum level of IL6 can be used as
diagnostic marker for diabetic painful neuropathy.